CAMP
CAMP4 THERAPEUTICS CORPORATION7.01
+0.26+3.85%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
328.64MP/E (TTM)
-Basic EPS (TTM)
-10.85Dividend Yield
0%Recent Filings
8-K
Appoints finance expert director
CAMP4 Therapeutics appointed Michael MacLean, a biotech finance veteran with 35+ years as CFO at Avidity Biosciences and others, as Class III director effective April 1, 2026, expanding the board to nine and adding him to Audit and Compensation Committees. He gets an option for 56,000 shares vesting over three years. Board gains deep public reporting expertise.
8-K
CAMP4's 2025 results, cash boost
CAMP4 announced full-year 2025 results on March 5, 2026, reporting $109.5M cash extending runway into 2028, fueled by $17.5M GSK upfront for ASO collaboration targeting neurodegenerative and kidney diseases, plus $80M private placement and $30M offering proceeds. GLP tox studies for SYNGAP1 candidate CMP-002 progress toward Phase 1/2 trial in H2 2026. Paused CMP-001 investment. Net loss widened to $80.4M.
10-K
FY2025 results
CAMP4 Therapeutics reported FY2025 net loss of $80.4M, up from $51.8M in FY2024, driven by $29.8M non-cash expense from derivative tranche liability tied to September private placement; R&D expenses held steady at $38.2M despite pausing CMP-001 UCD program to prioritize SYNGAP1 lead CMP-002, now in GLP tox studies eyeing Phase 1/2 start H2 2026. Cash swelled to $109.5M post-IPO ($72.4M net), September PIPE ($46.7M net), and December offering ($28.1M net), funding ops into 2028. GSK collab delivered $17.5M upfront (deferred), with $440M milestones + royalties ahead; Fulcrum milestone added $0.6M revenue. No Q4 breakdowns disclosed. Clinical delays could stall momentum.
8-K
Corporate presentation updated
CAMP4 Therapeutics updated its corporate presentation on January 9, 2026, furnishing it as Exhibit 99.1 under Item 7.01 for Regulation FD compliance. The deck, available on the company's investor website, summarizes business updates. No specific details disclosed in filing. Information furnished, not filed.
8-K
CAMP4 relocates to bigger Watertown lab
CAMP4 Therapeutics signed leases on December 22, 2025, to exit its 30,760 sq ft Cambridge space early—targeted 180 days later—for a larger 44,000 sq ft lab/office in Watertown through June 2030 at $40/sq ft base rent, rising 3% yearly. It pays ARE $2.1M fee for 14 months extra rent abatement, while abating Cambridge rent from October 2025. Strategic upgrade. Risks hinge on no defaults.
ARMP
Armata Pharmaceuticals, Inc.
5.72-0.44
CCCC
C4 Therapeutics, Inc.
2.26-0.17
CMPS
COMPASS Pathways Plc - American
6.39-0.20
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
DSGN
Design Therapeutics, Inc.
9.62+0.50
NGNE
Neurogene Inc.
19.53-0.73
NVCT
Nuvectis Pharma, Inc.
7.69+0.04
RGNX
REGENXBIO Inc.
14.11+0.28
UPB
Upstream Bio, Inc.
29.32+2.12
XFOR
X4 Pharmaceuticals, Inc.
3.71-0.05